Vepugratinib

Vepugratinib
Clinical data
Other names	LOX-24350; LOXO-435; LY-3866288
Identifiers
	IUPAC name 4-[4-[3-chloro-4-[(1S)-1-(5-fluoro-2-pyridinyl)-2-hydroxyethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyltriazol-1-yl]piperidine-1-carbonitrile;
CAS Number	2833703-74-3;
PubChem CID	171074967;
IUPHAR/BPS	14366;
UNII	SN3C4ZE59P;
KEGG	D13203;
ChEMBL	ChEMBL6168351;
Chemical and physical data
Formula	C23H22ClFN8O2
Molar mass	496.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(N=NN1C2CCN(CC2)C#N)C3=CN4C(=C(C=N4)Cl)C(=C3)O[C@H](CO)C5=NC=C(C=C5)F;
	InChI InChI=InChI=1S/C23H22ClFN8O2/c1-14-22(29-30-33(14)17-4-6-31(13-26)7-5-17)15-8-20(23-18(24)10-28-32(23)11-15)35-21(12-34)19-3-2-16(25)9-27-19/h2-3,8-11,17,21,34H,4-7,12H2,1H3/t21-/m1/s1; Key:OYUCEQFRNJABJW-OAQYLSRUSA-N;

Vepugratinib is an investigational new drug that is being evaluated by Loxo Oncology for the treatment of genitourinary cancer.^[1] It is a fibroblast growth factor receptor 3 antagonist.^[1]^[2]

References

1 2 "Vepugratinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
↑ Chen L (November 2025). "Next-generation isoform-selective fibroblast growth factor receptor inhibitors". Trends in Pharmacological Sciences. 46 (11): 1091–1104. doi:10.1016/j.tips.2025.09.004. PMID 41125482.